Primary care provider Cano Health may follow Babylon Health down the same drain. After announcing a horrible Q2 last week, Cano Health in its press release finally admitted that their “liquidity is not sufficient to cover the Company’s operating, investing, and financing uses for the next 12 months”. 700 people, or 17% of its current workforce, will be laid off during Q3 as part of restructuring.
Cano, or what will be left of it after the following, is officially up for sale either whole or partially, ASAP.
- Cano will exit three states and one territory: California, New Mexico, and Illinois by the fall which presently have 5,000 members and 17 medical centers. Puerto Rico, with 8,000 members in an unenumerated number of affiliated practices, will wind up as of 1 January 2024. 40% of the layoffs they attribute to the exits, the rest to consolidation of and other downsizing of administrative operations.
- Downsizing Texas and Nevada medical operations.
- Massive restructuring in their core market of Florida.
- Reducing their current 169 medical centers to 136 by the end of year
- Their Q2 net loss was $270.7 million, adding on to Q1’s $60.6 million net loss [TTA 12 May]. This compares to prior year net loss of $14.6 million, an increase of over $256 million or over 1800 percent. This was attributed to lower Medicare Risk Adjustment (MRA) revenue and higher than expected medical expenses, along with adjustments and higher than forecast interest expenses.
- Their adjusted EBITDA was equally dismal: $149.7 million, compared to $9.9 million profit in Q2 2022 and Q1’s $5 million,
- Liquidity is $101 million as of 9 August–not enough to conduct business for 12 months (and an educated guess, to 31 December. Their line of credit (CS Revolving Line of Credit) is fully drawn while they engage in a rather complicated negotiation of something termed the “2023 Side-Car Amendment”. Supposedly this will be paid down ‘significantly’ by September. Despite this, here is the cautionary statement regarding the sale of the company or assets, which would not be in their release unless the company was truly in a deep hole indeed:
The Company has not set a timetable for the conclusion of this process and there is no assurance that the process will result in any transaction. Cano Health does not intend to comment while it undergoes this process, unless required by law or the Company determines that it would be in its best interests.
Cano stock sank to the $0.40 to $0.45 range from a year ago in October of close to $10.
A stock commentator quoted in Becker’s (Seeking Alpha, paywalled) posits that any sale would be just about impossible without Chapter 11 bankruptcy. Logically, any investor would prefer to pick up assets at a fire sale without the encumbrances of a workforce, as brutal as that sounds. But the value of Cano is in its practices and workforce delivering primary care. Another wrinkle is that Cano is in current CMS agreements on Medicare Advantage and ACO REACH contracts that would have to be assumed. One would also assume that their search for a new CEO to replace interim Mark Kent is also on hold.
Not a peep yet from the Cano 3 (resigned directors Barry Sternlicht, Elliot Cooperstone, and Lewis Gold), but observers expect they will have something to say with 35% of near-worthless shares in their collective portfolios. Medical Economics, Reuters, FierceHealthcare, Healthcare Dive Our prior coverage on CEO Marlow Hernandez’s ‘step down’ on 21 June has links to earlier stories.
This story is developing and will be updated.